RedHill Biopharma (RDHL) Change in Receivables (2017 - 2022)

RedHill Biopharma (RDHL) has 6 years of Change in Receivables data on file, last reported at $1.5 million in Q4 2022.

• On a quarterly basis, Change in Receivables rose 190.55% year-over-year to $1.5 million in Q4 2022; TTM through Dec 2022 was -$2.8 million, a 5.83% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 4244.23% from the prior year.
• Change in Receivables for Q4 2022 stood at $1.5 million, up from -$2.3 million in the prior quarter.
• Over the last five years, Change in Receivables for RDHL reached as high as $6.1 million in Q3 2020 and fell as low as -$16.9 million in Q2 2020.
• Historically, Change in Receivables has averaged -$1.6 million across 5 years, with a median of -$202500.0 in 2018.
• On a YoY basis, Change in Receivables climbed as much as 5487.27% in 2020 and fell as far as 4371.35% in 2020.
• Year by year, Change in Receivables stood at $962000.0 in 2018, then slumped by 137.73% to -$363000.0 in 2019, then slumped by 4371.35% to -$16.2 million in 2020, then jumped by 89.9% to -$1.6 million in 2021, then jumped by 190.55% to $1.5 million in 2022.
• Per Business Quant data, the three most recent Change in Receivables figures were $1.5 million in Q4 2022, -$2.3 million in Q3 2022, and -$7.8 million in Q2 2022.